Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.
about
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesHuman immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesDermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.Immunization with a Mixture of HIV Env DNA and VLP Vaccines Augments Induction of CD8 T Cell Responses.Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteinsEvidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaquesEnhancement of mucosal immunization with virus-like particles of simian immunodeficiency virusSequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodiesAbrogation of contaminating RNA activity in HIV-1 Gag VLPs.Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectorsImmunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles.Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteinsA comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccineProtection against filovirus infection: virus-like particle vaccines.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Developments in virus-like particle-based vaccines for HIV.Justification for the inclusion of Gag in HIV vaccine candidates.Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles.Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1.
P2860
Q21089693-CC8A6FA3-443D-4562-BF5B-105981A965C5Q27489000-28E7B6C8-A592-4EDF-B828-21D01F92A6D4Q29619015-C3D24014-0174-49C3-AB6C-F9E28C656815Q30408029-59BD351C-DBCE-42AA-BBE3-D8029E8BC952Q33876108-9697C6C0-8879-41BB-87A7-A7C1D98F5215Q34142795-18E8D251-CECA-47AD-A708-09661838A5E1Q34343020-B3FF33BC-A388-4821-937E-A7B53DF607DCQ34462167-CCD9C3C5-419C-4AEE-B45D-0C17020D6931Q34744920-81081512-0D7F-46B8-9BAB-339B72CFA5C4Q34982715-A78DFC44-AE6F-494B-AB86-5B3B54B31852Q35478282-64E79549-D9AB-4E3B-901D-1F0D88910AC6Q35914427-D0DDD8E3-B96C-4594-AA7E-468F85F644CDQ35960908-0751D83E-393F-4ED7-A381-DD990E70D7E3Q35985896-410F98C7-1627-4729-817D-E984B2BDDFBAQ36149102-2CE30602-E9BA-4667-B9CF-149C77DA183EQ36155445-312A53CD-8091-46C7-A0E1-99AC4A2005DAQ36177537-4800B102-6C63-45D2-9D84-CFFA57B873A6Q37130463-9FF92191-E4AB-468D-B017-59E80D4F2886Q37951525-D636ECE7-1C7A-45EE-AF05-833C5F75415CQ38081965-8A968898-62F8-4A2F-A47E-C59B898ABDD4Q38662319-5461DED7-6B20-4E0E-B9FD-D92B325C078CQ39748804-0D42AF6D-E7E2-40ED-A179-3F9B7C49221AQ45411816-699A3CB3-45CF-4448-92B6-6FD01FE14FBE
P2860
Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Induction of neutralizing anti ...... rus type 1 in rhesus macaques.
@ast
Induction of neutralizing anti ...... rus type 1 in rhesus macaques.
@en
type
label
Induction of neutralizing anti ...... rus type 1 in rhesus macaques.
@ast
Induction of neutralizing anti ...... rus type 1 in rhesus macaques.
@en
prefLabel
Induction of neutralizing anti ...... rus type 1 in rhesus macaques.
@ast
Induction of neutralizing anti ...... rus type 1 in rhesus macaques.
@en
P2093
P2860
P1433
P1476
Induction of neutralizing anti ...... rus type 1 in rhesus macaques.
@en
P2093
B Rovinski
H L Robinson
J T Safrit
J Tartaglia
P2860
P304
P356
10.1128/JVI.75.13.5879-5890.2001
P577
2001-07-01T00:00:00Z